207 related articles for article (PubMed ID: 27422767)
1. Glucagonoma syndrome: a review and update on treatment.
John AM; Schwartz RA
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2016-2022. PubMed ID: 27422767
[TBL] [Abstract][Full Text] [Related]
2. Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.
V'lckova-Laskoska M; Balabanova-Stefanova M; Arsovska-Bezhoska I; Caca-Biljanovska N; Laskoski D
Acta Dermatovenerol Croat; 2018 Dec; 26(4):329-332. PubMed ID: 30665484
[TBL] [Abstract][Full Text] [Related]
3. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.
Eldor R; Glaser B; Fraenkel M; Doviner V; Salmon A; Gross DJ
Clin Endocrinol (Oxf); 2011 May; 74(5):593-8. PubMed ID: 21470282
[TBL] [Abstract][Full Text] [Related]
4. Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.
Tremblay C; Marcil I
J Cutan Med Surg; 2017; 21(6):559-561. PubMed ID: 28662584
[TBL] [Abstract][Full Text] [Related]
5. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
Tseng HC; Liu CT; Ho JC; Lin SH
Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
[TBL] [Abstract][Full Text] [Related]
6. [A clinical analysis of glucagonoma syndrome (four cases reported)].
Ma DL; Zeng JY; Wang BX; Fang K
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):210-3. PubMed ID: 12905724
[TBL] [Abstract][Full Text] [Related]
7. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome.
Remes-Troche JM; García-de-Acevedo B; Zuñiga-Varga J; Avila-Funes A; Orozco-Topete R
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):591-5. PubMed ID: 15324403
[TBL] [Abstract][Full Text] [Related]
8. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
Tolliver S; Graham J; Kaffenberger BH
Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
[TBL] [Abstract][Full Text] [Related]
9. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.
Tierney EP; Badger J
MedGenMed; 2004 Sep; 6(3):4. PubMed ID: 15520626
[TBL] [Abstract][Full Text] [Related]
10. Glucagonoma and pseudoglucagonoma syndrome.
Echenique-Elizondo M; Tuneu Valls A; Elorza Orúe JL; Martinez de Lizarduy I; Ibáñez Aguirre J
JOP; 2004 Jul; 5(4):179-85. PubMed ID: 15254346
[TBL] [Abstract][Full Text] [Related]
11. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.
Li W; Yang X; Deng Y; Jiang Y; Xu G; Li E; Wu Y; Ren J; Ma Z; Dong S; Han L; Ma Q; Wu Z; Wang Z
Sci Rep; 2022 May; 12(1):9053. PubMed ID: 35641533
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
Oberkirchner U; Linder KE; Zadrozny L; Olivry T
Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
[TBL] [Abstract][Full Text] [Related]
14. The glucagonoma syndrome. Clinical and pathologic features in 21 patients.
Wermers RA; Fatourechi V; Wynne AG; Kvols LK; Lloyd RV
Medicine (Baltimore); 1996 Mar; 75(2):53-63. PubMed ID: 8606627
[TBL] [Abstract][Full Text] [Related]
15. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
Kindmark H; Sundin A; Granberg D; Dunder K; Skogseid B; Janson ET; Welin S; Oberg K; Eriksson B
Med Oncol; 2007; 24(3):330-7. PubMed ID: 17873310
[TBL] [Abstract][Full Text] [Related]
16. Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene.
Tamura A; Ogasawara T; Fujii Y; Kaneko H; Nakayama A; Higuchi S; Hashimoto N; Miyabayashi Y; Fujimoto M; Komai E; Kono T; Sakuma I; Nagano H; Suzuki S; Koide H; Yokote K; Iseki K; Oguma R; Matsue H; Nojima H; Sugiura K; Yoshitomi H; Ohtsuka M; Rahmutulla B; Kaneda A; Inoshita N; Ogawa S; Tanaka T
J Clin Endocrinol Metab; 2018 Jul; 103(7):2417-2423. PubMed ID: 29688432
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience in diagnosis and treatment of glucagonoma syndrome.
Zhang M; Xu X; Shen Y; Hu ZH; Wu LM; Zheng SS
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):473-5. PubMed ID: 15313692
[TBL] [Abstract][Full Text] [Related]
18. Glucagonoma syndrome: a case report.
Shyr YM; Su CH; Lee CH; Wu CW; Lui WY
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):639-43. PubMed ID: 10502856
[TBL] [Abstract][Full Text] [Related]
19. Treatment of necrolytic migratory erythema in glucagonoma syndrome.
Shepherd ME; Raimer SS; Tyring SK; Smith EB
J Am Acad Dermatol; 1991 Nov; 25(5 Pt 2):925-8. PubMed ID: 1761771
[TBL] [Abstract][Full Text] [Related]
20. Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema.
Chen HW; Chen HW; Su DH; Shun CT; Liu KL
J Formos Med Assoc; 2005 May; 104(5):363-6. PubMed ID: 15959605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
